In February 2026, Humacyte announced that the U.S. Department of Defense’s Fiscal Year 2026 Appropriations Act allocates dedicated funding to evaluate and incorporate biologic vascular repair ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results